Fig. 2

The effect of celecoxib and imatinib on human CML patient samples. a Mononuclear cells extracted from human CML patient samples and were treated with 0, 40, 60, 80, 100 μM celecoxib or 0, 1.6, 3.2, 6.4, 12.8 μM imatinib for 24, 48 h, then followed with MTT assay. Data were mean ± SD (n = 5). **p < 0.01, ***p < 0.001. b The sixth human CML patient sample was treated with 0, 40, 60, 80, 100 μM celecoxib for 24 h. Annexin V/PI assays was performed by flow cytometry